Akeso IncAkeso Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The analysis of Akeso Inc was assembled by All Street Sevva using leading Cognitive Robots. The assessment of Akeso Inc uses data from across the internet and also from available documents by Akeso Inc. The Disclosure score covers 17 United Nations SDGs including: 'No Poverty', 'Responsible Production & Consumption' and 'Life on Land'.

Akeso Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.9; made up of an environmental score of 4.6, social score of 8.0 and governance score of 5.0.

SDG Transparency Score for Akeso Inc 
Low
0 - 3

5.9

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Akeso Inc 
4.6

Environmental

8.0

Social

5.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
669Viridian Therapeutics Inc
6.0
High
669Vistin Pharma ASA
6.0
High
716Akeso Inc
5.9
High
716Alfresa Holdings Corp
5.9
High
716Aurora Cannabis Inc
5.9
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Akeso Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Akeso Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Akeso Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Akeso Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Akeso Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Akeso Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Akeso Inc offer flexible work?

LockedSign up for free to unlock

Does Akeso Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Akeso Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Akeso Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Akeso Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Akeso Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Akeso Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Akeso Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Akeso Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Akeso Inc disclose water use targets?

LockedSign up for free to unlock

Does Akeso Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Akeso Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Akeso Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Akeso Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Akeso Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Akeso Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Akeso Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Akeso Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Akeso Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Akeso Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Akeso Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Akeso Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Akeso Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Akeso Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Akeso Inc disclose its waste policy?

LockedSign up for free to unlock

Does Akeso Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Akeso Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Akeso Inc disclose energy use targets?

LockedSign up for free to unlock

Does Akeso Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Akeso Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Akeso Inc
These potential risks are based on the size, segment and geographies of the company.

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

Sorry!

Failed to process!